{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Autolus Therapeutics plc"},"Symbol":{"label":"Symbol","value":"AUTL"},"Address":{"label":"Address","value":"191 WOOD LANE THE MEDIAWORKS, LONDON, W12 7FP, United Kingdom"},"Phone":{"label":"Phone","value":"+44 2038296230"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 &amp; AUTO8."},"CompanyUrl":{"label":"Company Url","value":"https://www.autolus.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christian Martin Itin","title":"Chief Executive Officer &amp; Director"},{"name":"Christopher Vann","title":"Chief Operating Officer &amp; Senior Vice President"},{"name":"David Brochu","title":"Chief Technical Officer &amp; Senior Vice President"},{"name":"Martin PulT","title":"Chief Scientific Officer &amp; Senior Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}